{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:55:50Z","timestamp":1791327350710,"version":"4.3.1"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Eptinezumab is an intravenous anti-calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) approved for the prevention of episodic and chronic migraine. We aimed to explore the earliest changes in migraine pain intensity and associated symptoms during the first 30\u202fmin of eptinezumab infusion in a real-world setting, particularly when an acute migraine attack was ongoing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The BE-FREE study is an ongoing Italian observational, multicenter, independent, real-world, and prospective study. We enrolled patients affected with episodic migraine (EM) and chronic migraine (CM) who were experiencing an ongoing migraine attack. Eptinezumab was administered within 1\u201312\u202fh of the onset of the qualifying migraine attack. Data collected included monthly migraine days (MMDs), headache pain intensity, the number of monthly acute medications, and the use of concomitant or past standard preventive treatments (SPTs). The Numerical Rating Scale (NRS), associated symptoms, and pain freedom (PF) were recorded before infusion (T0) and at intervals of 10 (T10), 20 (T20), and 30 (T30) min during infusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We enrolled 31 patients (87% female), with a mean age of 43.1\u202fyears (SD 2.7); of these, 68% had CM. NRS scores significantly reduced at T10 (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.011) and T20 (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.004). Photophobia was less frequent at T10 (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.045), phonophobia at T20 (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.014), and osmophobia at T30 (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.046) compared with T0. PF was reported by 6.5% of patients at T10, 19.4% at T20, 29.0% at T30, and 19.4% at T60, T90, and T120.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The BE-FREE study results, representing the first real-world evidence, demonstrate the rapid effect of eptinezumab during the first 30\u202fmin of infusion in patients experiencing an ongoing migraine attack.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1784242","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:17:44Z","timestamp":1774930664000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Rapid effectiveness of eptinezumab to treat ongoing migraine attacks: preliminary data from an Italian multicenter real-world experience (the BE-FREE study)"],"prefix":"10.3389","volume":"17","author":[{"given":"Luisa","family":"Fofi","sequence":"first","affiliation":[{"name":"Neurosonology and Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Altamura","sequence":"additional","affiliation":[{"name":"Neurosonology and Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico","place":["Rome, Italy"]},{"name":"Department of Medicine and Surgery, Universit\u00e0 Campus Bio-Medico di Roma","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Marcosano","sequence":"additional","affiliation":[{"name":"Neurosonology and Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico","place":["Rome, Italy"]},{"name":"Department of Medicine and Surgery, Universit\u00e0 Campus Bio-Medico di Roma","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Doretti","sequence":"additional","affiliation":[{"name":"Department of Neurology-Laboratory of Neuroscience, IRCCS, Istituto Auxologico Italiano","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pistoia","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, Neurological Institute, University of L\u2019Aquila","place":["L\u2019Aquila, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Granato","sequence":"additional","affiliation":[{"name":"Headache Center, Neurology Clinic, University Hospital of Trieste, University of Trieste","place":["Trieste, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Guerzoni","sequence":"additional","affiliation":[{"name":"Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, Department of Specialist Medicines, AOU Policlinico di Modena","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Trimboli","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera-Universitaria \u201cRenato Dulbecco\u201d","place":["Catanzaro, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licia","family":"Grazzi","sequence":"additional","affiliation":[{"name":"Headache Center, Department of Neurology, IRCCS Foundation \u201cCarlo Besta\u201d Neurological Institute","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo Antonio","family":"Montisano","sequence":"additional","affiliation":[{"name":"Headache Center, Department of Neurology, IRCCS Foundation \u201cCarlo Besta\u201d Neurological Institute","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Avino","sequence":"additional","affiliation":[{"name":"SOC Neurologia, Ospedale Santo Stefano, USL Toscana Centro","place":["Prato, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Sebastianelli","sequence":"additional","affiliation":[{"name":"Department of Medico-Surgical Sciences and Biotechnologies, Polo Pontino ICOT, Sapienza University of Rome","place":["Latina, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Fasano","sequence":"additional","affiliation":[{"name":"Headache and Cerebrovascular Diseases Center, Neurology Unit 2, Careggi University Hospital","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa Maria","family":"Piella","sequence":"additional","affiliation":[{"name":"Department of Neurosciences \u201cRita Levi Montalcini\u201d, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierangelo","family":"Geppetti","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathobiology and Pain Research Center, College of Dentistry, New York University","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Brunelli","sequence":"additional","affiliation":[{"name":"Neurosonology and Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Francesco","family":"Iannone","sequence":"additional","affiliation":[{"name":"Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Vernieri","sequence":"additional","affiliation":[{"name":"Neurosonology and Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico","place":["Rome, Italy"]},{"name":"Department of Medicine and Surgery, Universit\u00e0 Campus Bio-Medico di Roma","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"ref1","article-title":"Summary of product characteristics: eptinezumab (VYEPTI)","year":"2023"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1124\/jpet.119.264671","article-title":"Pharmacologic characterization of ALD403, a potent neutralizing humanized monoclonal antibody against the calcitonin gene-related peptide","volume":"374","author":"Garcia-Martinez","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e00567","DOI":"10.1002\/prp2.567","article-title":"Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine","volume":"8","author":"Baker","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/head.14903","article-title":"Pharmacological differences and switching among anti-CGRP monoclonal antibodies: a narrative review","volume":"65","author":"Romozzi","year":"2025","journal-title":"Headache"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"11076","DOI":"10.1080\/21655979.2021.2006977","article-title":"The eptinezumab: CGRP complex structure\u2014the role of conformational changes in binding stabilization","volume":"12","author":"David","year":"2021","journal-title":"Bioengineered"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1001\/jama.2021.7665","article-title":"Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial","volume":"325","author":"Winner","year":"2021","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12883-022-02714-1","article-title":"Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial","volume":"22","author":"Ailani","year":"2022","journal-title":"BMC Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","article-title":"Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"21","author":"Ashina","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12883-022-02774-3","article-title":"Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab","volume":"22","author":"Blumenfeld","year":"2022","journal-title":"BMC Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"3331024251335927","DOI":"10.1177\/03331024251335927","article-title":"Effectiveness and tolerability of atogepant in the prevention of migraine: a real life, prospective, multicentric study (the STAR study)","volume":"45","author":"Vernieri","year":"2025","journal-title":"Cephalalgia"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","article-title":"Migraine and the trigeminovascular system-40 years and counting","volume":"18","author":"Ashina","year":"2019","journal-title":"Lancet Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s13311-018-0622-7","article-title":"The biology of monoclonal antibodies: focus on calcitonin gene-related peptide for prophylactic migraine therapy","volume":"15","author":"Raffaelli","year":"2018","journal-title":"Neurotherapeutics"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1784242\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:17:48Z","timestamp":1774930668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1784242\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":15,"alternative-id":["10.3389\/fneur.2026.1784242"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1784242","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"1784242"}}